Erratum to “Premonitory Symptoms in Migraine: Implications for Disease Burden and Cognitive Impairment, with Some Promising Answers”

Article information

Headache Pain Res. 2025;26(3):232-232

Publication date (electronic) : 2025 August 20

doi : https://doi.org/10.62087/hpr.2024.0031.e1

Utku Topbaş ¹

, Bahar Taşdelen ²

, Nevra Öksüz Gürlen ¹

, Aynur Özge^,¹

¹Department of Neurology, Mersin University School of Medicine, Mersin, Turkey

²Department of Biostatistics, Mersin University School of Medicine, Mersin, Turkey

Correspondence: Aynur Özge, M.D. Department of Neurology, Mersin University School of Medicine, Çiftlikköy Mah., MEÜ Çiftlikköy Kampüsü, 33110 Yenişehir/Mersin, Turkey Tel: +90-324-2410000 (1902), Fax: +90-3242410000-1907, E-mail: aozge@mersin.edu.tr

This is a correction to an already published paper (Headache Pain Res 2025;26(2):130-141; https://doi.org/10.62087/hpr.2024.0031). We found errors in the IQR values in Tables 1 and 3. Appropriately adjusted are as below.

Table 1.

Comparison of demographic features between the PS+ and PS– groups

Table 3.

Comparison of the PS+ and PS– groups in terms of migraine trigger factors

This error does not change the text and the conclusions of our paper. We apologize for the unintentional mistake and appreciate the opportunity to correct and clarify the issue.

Notes

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1.

Comparison of demographic features between the PS+ and PS– groups

Parameter	PS+ (n=139)	PS– (n=47)	p-value^†
Mean age (yr)	35.1±10.4	36.9±11.3	0.397
Female sex	117 (84.2)	42 (89.4)	0.477
Chronic migraine	28 (20.1)	10 (21.3)	0.837
Migraine with aura	51 (36.7)	8 (17.0)	0.017*
MMD (IQR)	5 (3–10)	6 (3–10)	0.889
VAS (IQR)	8 (7–9)	8 (7–10)	0.498
Oral preventatives: small molecule	73 (52.5)	16 (34.0)	0.042*
Onabotulinumtoxin-A	18 (12.9)	1 (2.1)	0.048*
GON blockage	27 (19.4)	11 (23.4)	0.677

Values are presented as mean±standard deviation, number (%), or median (IQR).

PS+, premonitory symptom positive; PS–, premonitory symptom negative; MMD, monthly migraine days; IQR, interquartile range; VAS, visual analogue score; GON, greater occipital nerve.

^*Asterisk indicates a statistically significant (p<0.05). ^†For parameters given as either mean±standard deviation or median (IQR), the Mann-Whitney U-test was used to obtain p-values. For parameters given as frequency, the chi-square test was used to obtain p-values.

Table 3.

Comparison of the PS+ and PS– groups in terms of migraine trigger factors

	PS+ (n=139)	PS– (n=47)	p-value^†
MIDAS (IQR)	26 (14–40)	16 (10–33.5)	0.05
Mig-SCOG (IQR)	10 (7–14)	7 (4–10)	<0.001*
EUROHIS-8 (IQR)	3.12 (2.75–3.62)	3.62 (3.12–4.00)	<0.001*

Values are presented as or median (IQR).

PS+, premonitory symptom positive; PS–, premonitory symptom negative; MIDAS, Migraine Disability Assessment Scale; IQR, interquartile range; Mig-SCOG, Migraine Attack Related Subjective Cognitive Scale; EUROHIS-8, European Health Impact Scale.

^*Asterisk indicates a statistically significant (p<0.05). ^†For parameters with IQR values, the significance between groups was tested with the Mann-Whitney U-test.